Latest Asx News

Orezone Gold Corporation reported a robust first half of 2025 with net earnings of $36.7 million and advanced its Bomboré mine expansion, while completing a significant ASX IPO.

Euro Manganese Inc. has bolstered its development of the Chvaletice Manganese Project with new financing and critical regulatory approvals, while progressing offtake discussions amid ongoing market uncertainties.

Temple & Webster has reported a robust 21% revenue increase in FY25, alongside a near sixfold jump in net profit, setting a confident tone for FY26 with strong early trading and an optimistic outlook.

Telstra Group Limited has released its full-year financial results for FY2025, setting the stage for an in-depth analyst briefing and webcast. Investors await detailed insights into the company’s performance and strategic direction.

Vista Group International reports robust H1 2025 results with strong revenue growth and margin expansion, driven by accelerating client adoption of its Vista Cloud platform and a new Embedded Payments initiative.

HomeCo Daily Needs REIT posted solid FY25 results with growth in funds from operations and distributions per unit, underpinned by strong portfolio valuation and operational metrics. The REIT’s FY26 guidance signals continued growth supported by a robust development pipeline and disciplined capital management.

HomeCo Daily Needs REIT has delivered on its FY25 financial guidance, showcasing strong operational metrics and a robust development pipeline that sets the stage for growth in FY26.

InFocus Group Holdings addresses ASX concerns over a former director's non-disclosure of trading activity and provides detailed due diligence on key contract counterparties.

Pacific Smiles Group has reported solid FY25 financial results, with patient fees rising 8.7% and underlying EBITDA up 12.1%, reflecting strong operational momentum.

Citigroup Global Markets Australia has announced a fully franked dividend of AUD 2.2675 for RIO CitiFirst Self-Funding Instalment MINI warrants, aligning key dates with RIO ordinary shares.

Anatara Lifesciences reported a 35% rise in net loss to $1.95 million for FY25, following pivotal Phase II trial results for its GaRP product that missed the primary efficacy endpoint but showed promising secondary benefits. The company is advancing commercialisation efforts and launching a new anti-obesity project amid tightened cash reserves.

Eildon Capital Group has entered a joint venture to acquire a large sandalwood plantation in Queensland’s Burdekin Irrigation District, while unveiling a strategic update to its operating model aimed at driving disciplined growth and enhanced returns.